These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 25795760)

  • 1. Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages.
    Shi Y; Fan X; Deng H; Brezski RJ; Rycyzyn M; Jordan RE; Strohl WR; Zou Q; Zhang N; An Z
    J Immunol; 2015 May; 194(9):4379-86. PubMed ID: 25795760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-B7-H4 checkpoint synergizes trastuzumab treatment to promote phagocytosis and eradicate breast cancer.
    Hu X; Liu Y; Zhang X; Kong D; Kong J; Zhao D; Guo Y; Sun L; Chu L; Liu S; Hou X; Ren F; Zhao Y; Lu C; Zhai D; Yuan X
    Neoplasia; 2020 Nov; 22(11):539-553. PubMed ID: 32966956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis.
    Tsao LC; Crosby EJ; Trotter TN; Agarwal P; Hwang BJ; Acharya C; Shuptrine CW; Wang T; Wei J; Yang X; Lei G; Liu CX; Rabiola CA; Chodosh LA; Muller WJ; Lyerly HK; Hartman ZC
    JCI Insight; 2019 Dec; 4(24):. PubMed ID: 31689243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.
    Nordstrom JL; Gorlatov S; Zhang W; Yang Y; Huang L; Burke S; Li H; Ciccarone V; Zhang T; Stavenhagen J; Koenig S; Stewart SJ; Moore PA; Johnson S; Bonvini E
    Breast Cancer Res; 2011; 13(6):R123. PubMed ID: 22129105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer.
    Junttila TT; Parsons K; Olsson C; Lu Y; Xin Y; Theriault J; Crocker L; Pabonan O; Baginski T; Meng G; Totpal K; Kelley RF; Sliwkowski MX
    Cancer Res; 2010 Jun; 70(11):4481-9. PubMed ID: 20484044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential regulation of human monocytes and NK cells by antibody-opsonized tumors.
    Yin J; Albers AJ; Smith TS; Riddell GT; Richards JO
    Cancer Immunol Immunother; 2018 Aug; 67(8):1239-1250. PubMed ID: 29855696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients.
    Petricevic B; Laengle J; Singer J; Sachet M; Fazekas J; Steger G; Bartsch R; Jensen-Jarolim E; Bergmann M
    J Transl Med; 2013 Dec; 11():307. PubMed ID: 24330813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.
    Luistro LL; Rosinski JA; Bian H; Bishayee S; Rameshwar P; Ponzio NM; Ritland SR
    Int J Oncol; 2012 Aug; 41(2):639-51. PubMed ID: 22580986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
    Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
    J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catecholamine-Induced β2-adrenergic receptor activation mediates desensitization of gastric cancer cells to trastuzumab by upregulating MUC4 expression.
    Shi M; Yang Z; Hu M; Liu D; Hu Y; Qian L; Zhang W; Chen H; Guo L; Yu M; Song L; Ma Y; Guo N
    J Immunol; 2013 Jun; 190(11):5600-8. PubMed ID: 23630346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
    Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of trastuzumab interchain disulfide bond cleavage on Fcγ receptor binding and antibody-dependent tumour cell phagocytosis.
    Suzuki M; Yamanoi A; Machino Y; Ootsubo M; Izawa K; Kohroki J; Masuho Y
    J Biochem; 2016 Jan; 159(1):67-76. PubMed ID: 26254483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
    Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF
    Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells.
    Hamano S; Mori Y; Aoyama M; Kataoka H; Tanaka M; Ebi M; Kubota E; Mizoshita T; Tanida S; Johnston RN; Asai K; Joh T
    Cancer Lett; 2015 Jan; 356(2 Pt B):846-54. PubMed ID: 25444894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
    Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
    Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation.
    Shi Y; Fan X; Meng W; Deng H; Zhang N; An Z
    Breast Cancer Res; 2014 Apr; 16(2):R33. PubMed ID: 24693969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages.
    Su S; Zhao J; Xing Y; Zhang X; Liu J; Ouyang Q; Chen J; Su F; Liu Q; Song E
    Cell; 2018 Oct; 175(2):442-457.e23. PubMed ID: 30290143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel method for determining antibody-dependent cellular phagocytosis.
    Kamen L; Myneni S; Langsdorf C; Kho E; Ordonia B; Thakurta T; Zheng K; Song A; Chung S
    J Immunol Methods; 2019 May; 468():55-60. PubMed ID: 30880262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro.
    Leidi M; Gotti E; Bologna L; Miranda E; Rimoldi M; Sica A; Roncalli M; Palumbo GA; Introna M; Golay J
    J Immunol; 2009 Apr; 182(7):4415-22. PubMed ID: 19299742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy.
    Fan X; Brezski RJ; Fa M; Deng H; Oberholtzer A; Gonzalez A; Dubinsky WP; Strohl WR; Jordan RE; Zhang N; An Z
    Breast Cancer Res; 2012 Aug; 14(4):R116. PubMed ID: 22873525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.